CoChat
Sign Up
Cited by 140Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies ResearchNeutropenia and Cancer Infections

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Open access
Lancman, Guido, Parsa, Kian, Kotlarz, Krzysztof, Avery, Lisa, Lurie, Alaina, Lieberman-Cribbin, Alex, Cho, Hearn Jay, Parekh, Samir S., Richard, Shambavi, Richter, Joshua, Rodriguez, Cesar, Rossi, Adriana, Sanchez, Larysa J., Thibaud, Santiago, Jagannath, Sundar, Chari, Ajai·2023·Blood Cancer Discovery
DOI 10.1158/2643-3230.bcd-23-0049PMC PMC10618720

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all infections and their risk factors, and evaluated the impact of infection prophylaxis in patients treated with BCMA-targeted BiAbs. Among 37 patients, 15 (41%) experienced a grade 3–5 infection, with two infection-related deaths during deep remissions. Most (84%) infections occurred during disease remissions. The cumulative probability of grade 3–5 infection increased over time with no plateau. Among responders (n = 26), profound hypogammaglobulinemia occurred in 100% and continued throughout the entire duration of treatment. During periods when patients were receiving intravenous immunoglobulin (IVIg), the rate of grade 3–5 infections was 90% lower than during observation (incidence rate ratio, 0.10; 95% confidence interval, 0.01–0.80; P = 0.0307). No other risk factors for infection were identified. This study demonstrates that profound hypogammaglobulinemia is universal with BCMA-targeted BiAbs, with intravenous immunoglobulin potentially abrogating most of the infection risk. Significance: To the best of our knowledge, this is the first study to comprehensively analyze risk factors and mitigation strategies to prevent infections in myeloma patients receiving anti-BCMA bispecific antibodies. Profound and prolonged hypogammaglobulinemia was universal among responders, while immunoglobulin replacement was associated with 90% lower rates of grade 3–5 infections. See related commentary by Garfall and Stadtmauer, p. 427 . This article is featured in Selected Articles from This Issue, p. 419

Overview

Integrity signals

Registry

Crossref · 10.1158/2643-3230.bcd-23-0049

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 43 references

Cited by

Sorted by citations

See all 140

Related

Metadata

Authors
Lancman, G., Parsa, K., Kotlarz, K., Avery, L., Lurie, A., Lieberman-Cribbin, A., Cho, H. J., Parekh, S. S., Richard, S., Richter, J., Rodriguez, C., Rossi, A., Sanchez, L. J., Thibaud, S., Jagannath, S., & Chari, A.
Affiliations
  • Princess Margaret Cancer Centre (CA)
  • Icahn School of Medicine at Mount Sinai (US)
  • Wrocław University of Environmental and Life Sciences (PL)
  • University Health Network (CA)
  • Tisch Cancer Institute (US)
  • University of California, San Francisco (US)
Corresponding author
Lancman, Guido
ORCID
Venue
Blood Cancer Discovery
Publisher
American Association for Cancer Research (AACR)
Published
2023-09-28
Volume
4
Issue
6
Pages
440-451
ISSN
  • 2643-3230 (ISSN-L)
  • 2643-3249
DOI
10.1158/2643-3230.bcd-23-0049
PMC
PMC10618720
OpenAlex
W4387128075
Cited by
140
References
43
Citations by year
2026: 50 · 2025: 49 · 2024: 35 · 2023: 6
FWCI
28.92
Type
journal article
Language
en
Open access
Locations
  • Blood Cancer Discovery (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
Polish National Agency for Academic Exchange (Preludium BIS 1 (2019/35/O/NZ9/00237))
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
Keywords
intravenous immunoglobulin, multiple myeloma, serious infections, hypogammaglobulinemia, infection control, infection risk factors, relapsed/refractory multiple myeloma, immunoglobulin replacement therapy
MeSH terms
Agammaglobulinemia, Humans, Multiple Myeloma, Retrospective Studies, Immunoglobulins, Intravenous, Antibodies, Bispecific, B-Cell Maturation Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review